Compositon/Ingredients: Fluoxetine

• Depression,
• Bulimia nervosa,
• Obsessive-compulsive disorder,
• Panic disorder,
• Premenstrual dysphoric disorder.

• Hypersensitivity to fluoxetine or any of its excipients.
• Monoamine oxidase inhibitors (MAOI): Fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI.
• Concomitant use in patients taking pimozide is contraindicated.
• Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued.

Depression

• Adults:
  20mg once daily in the morning.
  If no clinical response is seen after several weeks, the daily dose may be gradually increased, up to a maximum of 80mg daily (60mg in the elderly).
  Doses above 20mg daily may be given in 2 divided doses, for example in the morning and at noon, or as a once daily dose.
• Children aged 8 years and over:
  Initial doses of 10mg should be increased to 20mg daily after 1 week (except in low-weight children when such increases should not be made for several weeks, and then only if the clinical response is insufficient).

Bulimia nervosa:

• 60mg once daily.

Obsessive-compulsive disorder:

• Adults:
  The initial dose of fluoxetine is 20mg once daily increased after several weeks if there is no response to up to 60mg daily. Up to 80mg daily has been used, sometimes divided into 2 doses.
• Children aged 7 years and over:
  The starting dose is 10mg daily; in low weight children this is increased after several weeks to 20 to 30mg daily, if required. Adolescents and heavier children may be increased to 20mg daily after 2 weeks; further increases to 60mg daily may be made after several weeks, as necessary.

Panic disorder:

• The initial dose is 10 mg once daily.
• After a week the dose should be increased to 20 mg daily; further increases to 60 mg daily may be considered after several weeks if no improvement is seen.

Premenstrual dysphoric disorder:

• 20mg daily.
• For each new cycle, fluoxetine should be started 14 days before the onset of menstruation and continued until the first full day of menstruation.
• Treatment may be continued for 6 months; benefit should then be reassessed before continuing further.

Elderly patients:

• A lower or less frequent dosage is recommended.

• Patients with cardiac disease or a history of bleeding disorders.
• Patients with angle-closure glaucoma.
• Patients with diabetes since SSRIs may alter glycaemic control.
• Patients with impaired hepatic function.

Store at temperature below 30°C, protect from light.